PL2478905T3 - Sposób leczenia białaczki opornej na imatynib, wykorzystujący 4-aminochinolino-3-karbonitryle - Google Patents

Sposób leczenia białaczki opornej na imatynib, wykorzystujący 4-aminochinolino-3-karbonitryle

Info

Publication number: PL2478905T3
Authority: PL; Poland
Prior art keywords: carbonitriles; aminoquinoline; treatment; resistant leukemia; imatinib resistant
Prior art date: 2007-06-01

Application number

PL12160638T

Other languages

English (en)

Inventor

Becker Hewes

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-01

Filing date

2008-05-30

Publication date

2014-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2478905(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-05-30 Application filed by Wyeth Llc filed Critical Wyeth Llc

2014-10-31 Publication of PL2478905T3 publication Critical patent/PL2478905T3/pl

Links

239000005517 L01XE01 - Imatinib Substances 0.000 title 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 title 1
229960002411 imatinib Drugs 0.000 title 1
208000032839 leukemia Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL12160638T 2007-06-01 2008-05-30 Sposób leczenia białaczki opornej na imatynib, wykorzystujący 4-aminochinolino-3-karbonitryle PL2478905T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US93265007P	2007-06-01	2007-06-01
EP08769857A EP2152267A2 (en)	2007-06-01	2008-05-30	Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
EP12160638.8A EP2478905B1 (en)	2007-06-01	2008-05-30	Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Publications (1)

Publication Number	Publication Date
PL2478905T3 true PL2478905T3 (pl)	2014-10-31

Family

ID=39639071

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL15191756T PL3002009T3 (pl)	2007-06-01	2008-05-30	Leczenie przewlekłej białaczki szpikowej opornej na imatynib z mutacją 1457T>C w genie bcrabl, wykorzystujące bosutynib
PL12160638T PL2478905T3 (pl)	2007-06-01	2008-05-30	Sposób leczenia białaczki opornej na imatynib, wykorzystujący 4-aminochinolino-3-karbonitryle

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL15191756T PL3002009T3 (pl)	2007-06-01	2008-05-30	Leczenie przewlekłej białaczki szpikowej opornej na imatynib z mutacją 1457T>C w genie bcrabl, wykorzystujące bosutynib

Country Status (23)

Country	Link
US (1)	US11103497B2 (pl)
EP (4)	EP3002009B1 (pl)
JP (3)	JP5888853B2 (pl)
KR (1)	KR101493543B1 (pl)
CN (1)	CN101686973B (pl)
AU (1)	AU2008260070B9 (pl)
BR (1)	BRPI0812355A2 (pl)
CA (3)	CA2688467C (pl)
CL (1)	CL2008001577A1 (pl)
CY (2)	CY1115251T1 (pl)
DK (2)	DK2478905T3 (pl)
ES (2)	ES2477567T3 (pl)
HU (1)	HUE055524T2 (pl)
IL (1)	IL202407A0 (pl)
MX (1)	MX2009013069A (pl)
PA (1)	PA8782301A1 (pl)
PL (2)	PL3002009T3 (pl)
PT (2)	PT3002009T (pl)
RU (1)	RU2464026C2 (pl)
SI (2)	SI3002009T1 (pl)
TW (1)	TW200908982A (pl)
WO (1)	WO2008150957A2 (pl)
ZA (1)	ZA200908480B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200908982A (en) *	2007-06-01	2009-03-01	Wyeth Corp	Treatment of imatinib resistant leukemia
WO2012122011A2 (en)	2011-03-04	2012-09-13	Glaxosmithkline Llc	Amino-quinolines as kinase inhibitors
TWI547494B (zh)	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
TW201425307A (zh)	2012-09-13	2014-07-01	Glaxosmithkline Llc	作為激酶抑制劑之胺基－喹啉類
TWI592417B (zh)	2012-09-13	2017-07-21	葛蘭素史克智慧財產發展有限公司	胺基喹唑啉激酶抑制劑之前藥
TWI630203B (zh)	2013-02-21	2018-07-21	葛蘭素史克智慧財產發展有限公司	做為激酶抑制劑的喹唑啉類
KR101733665B1 (ko) *	2015-05-06	2017-05-10	재단법인 지능형 바이오 시스템 설계 및 합성 연구단	진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
PH12022550370A1 (en) *	2019-08-22	2023-03-06	Biohaven Therapeutics Ltd	Molecules that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders
CN115944636A (zh) *	2022-11-01	2023-04-11	华南师范大学	博舒替尼在抑制i-motif结构上的应用
WO2025024311A2 (en) *	2023-07-21	2025-01-30	Icahn School Of Medicine At Mount Sinai	G9a/glp inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
US6297258B1 (en)	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
PL207720B1 (pl) *	2001-01-25	2011-01-31	Bristol Myers Squibb Co	Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej
EP2290056A3 (en) *	2001-10-05	2011-06-01	Novartis AG	Mutated Abl kinase domains
TWI275390B (en) *	2002-04-30	2007-03-11	Wyeth Corp	Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) *	2003-07-09	2005-01-13	Kane John Richard	Method and apparatus for providing access to personal information
BRPI0416289A (pt) *	2003-11-06	2007-01-23	Wyeth Corp	4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)
EP1877075A4 (en)	2005-04-25	2008-07-30	Pfizer	ANTIBODY TO MYOSTATIN
BRPI0610828A2 (pt) *	2005-05-16	2010-07-27	Irm Llc	compostos e composições como inibidores de proteìna quinase
WO2007011765A2 (en)	2005-07-15	2007-01-25	Bristol-Myers Squibb Company	Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
ES2533464T3 (es)	2005-10-06	2015-04-10	Eli Lilly And Company	Anticuerpos anti-miostatina
US20100029676A1 (en)	2005-11-04	2010-02-04	Sawyers Charles L	T315a and f317i mutations of bcr-abl kinase domain
TW200908982A (en) *	2007-06-01	2009-03-01	Wyeth Corp	Treatment of imatinib resistant leukemia

2008
- 2008-05-30 TW TW097120369A patent/TW200908982A/zh unknown
- 2008-05-30 DK DK12160638.8T patent/DK2478905T3/da active
- 2008-05-30 EP EP15191756.4A patent/EP3002009B1/en active Active
- 2008-05-30 PL PL15191756T patent/PL3002009T3/pl unknown
- 2008-05-30 JP JP2010510505A patent/JP5888853B2/ja active Active
- 2008-05-30 KR KR1020097027540A patent/KR101493543B1/ko active Active
- 2008-05-30 WO PCT/US2008/065215 patent/WO2008150957A2/en not_active Ceased
- 2008-05-30 ES ES12160638.8T patent/ES2477567T3/es active Active
- 2008-05-30 ES ES15191756T patent/ES2881391T3/es active Active
- 2008-05-30 CA CA2688467A patent/CA2688467C/en active Active
- 2008-05-30 PT PT151917564T patent/PT3002009T/pt unknown
- 2008-05-30 SI SI200832178T patent/SI3002009T1/sl unknown
- 2008-05-30 PL PL12160638T patent/PL2478905T3/pl unknown
- 2008-05-30 CN CN2008800219346A patent/CN101686973B/zh active Active
- 2008-05-30 SI SI200831212T patent/SI2478905T1/sl unknown
- 2008-05-30 MX MX2009013069A patent/MX2009013069A/es active IP Right Grant
- 2008-05-30 RU RU2009144128/15A patent/RU2464026C2/ru active
- 2008-05-30 EP EP08769857A patent/EP2152267A2/en not_active Withdrawn
- 2008-05-30 CL CL200801577A patent/CL2008001577A1/es unknown
- 2008-05-30 DK DK15191756.4T patent/DK3002009T3/da active
- 2008-05-30 CA CA2868899A patent/CA2868899C/en active Active
- 2008-05-30 HU HUE15191756A patent/HUE055524T2/hu unknown
- 2008-05-30 US US12/129,935 patent/US11103497B2/en active Active
- 2008-05-30 AU AU2008260070A patent/AU2008260070B9/en active Active
- 2008-05-30 EP EP14167958.9A patent/EP2777704A3/en not_active Withdrawn
- 2008-05-30 BR BRPI0812355-1A2A patent/BRPI0812355A2/pt not_active Application Discontinuation
- 2008-05-30 CA CA2964162A patent/CA2964162C/en active Active
- 2008-05-30 PA PA20088782301A patent/PA8782301A1/es unknown
- 2008-05-30 PT PT121606388T patent/PT2478905E/pt unknown
- 2008-05-30 EP EP12160638.8A patent/EP2478905B1/en active Active
2009
- 2009-11-29 IL IL202407A patent/IL202407A0/en unknown
- 2009-11-30 ZA ZA200908480A patent/ZA200908480B/xx unknown
2014
- 2014-01-31 JP JP2014016309A patent/JP2014111629A/ja active Pending
- 2014-06-03 CY CY20141100395T patent/CY1115251T1/el unknown
2015
- 2015-11-24 JP JP2015229117A patent/JP2016074700A/ja active Pending
2021
- 2021-08-03 CY CY20211100693T patent/CY1124391T1/el unknown

Also Published As

Publication number	Publication date
CN101686973B (zh)	2013-06-19
AU2008260070B9 (en)	2012-01-19
BRPI0812355A2 (pt)	2015-01-27
EP2478905A2 (en)	2012-07-25
DK3002009T3 (da)	2021-08-02
HUE055524T2 (hu)	2021-11-29
EP3002009B1 (en)	2021-07-07
CL2008001577A1 (es)	2008-07-25
RU2464026C2 (ru)	2012-10-20
DK2478905T3 (da)	2014-06-30
KR101493543B1 (ko)	2015-02-13
EP2152267A2 (en)	2010-02-17
EP3002009A2 (en)	2016-04-06
CY1124391T1 (el)	2022-07-22
JP2016074700A (ja)	2016-05-12
ES2477567T3 (es)	2014-07-17
HK1142812A1 (en)	2010-12-17
CA2868899C (en)	2017-06-13
EP2478905A3 (en)	2013-01-16
CN101686973A (zh)	2010-03-31
JP2010529038A (ja)	2010-08-26
IL202407A0 (en)	2010-06-30
AU2008260070A1 (en)	2008-12-11
SI3002009T1 (sl)	2021-09-30
CA2868899A1 (en)	2008-12-11
SI2478905T1 (sl)	2014-07-31
CA2688467C (en)	2015-05-12
ZA200908480B (en)	2010-08-25
US20080318971A1 (en)	2008-12-25
AU2008260070B2 (en)	2011-08-18
PA8782301A1 (es)	2009-01-23
PL3002009T3 (pl)	2021-12-13
PT3002009T (pt)	2021-08-02
RU2009144128A (ru)	2011-07-20
JP5888853B2 (ja)	2016-03-22
TW200908982A (en)	2009-03-01
EP2478905B1 (en)	2014-05-14
EP2777704A2 (en)	2014-09-17
PT2478905E (pt)	2014-07-16
CA2964162C (en)	2019-12-31
CA2964162A1 (en)	2008-12-11
JP2014111629A (ja)	2014-06-19
EP3002009A3 (en)	2016-07-06
WO2008150957A3 (en)	2009-08-06
EP2777704A3 (en)	2015-01-21
MX2009013069A (es)	2010-03-17
KR20100017983A (ko)	2010-02-16
US11103497B2 (en)	2021-08-31
CY1115251T1 (el)	2017-01-04
WO2008150957A2 (en)	2008-12-11
CA2688467A1 (en)	2008-12-11
ES2881391T3 (es)	2021-11-29

Publication	Publication Date	Title
ZA200908480B (en)	2010-08-25	Treatment of imatinib resistant leukemia using 4-amino-quinoline-3-carbonitriles
ZA201101127B (en)	2012-05-30	Treatment of tailings streams
AP2874A (en)	2014-03-31	Antiviral compounds
SI2154969T1 (sl)	2016-02-29	Zdravljenje sinukleinopatij
PL2175851T3 (pl)	2013-11-29	Działanie na biofilm
IL202623A0 (en)	2010-06-30	Antiviral compounds
GB0715346D0 (en)	2007-09-19	Stimulator
EP2234623A4 (en)	2012-03-28	ANTIVIRAL CONNECTIONS
GB0718255D0 (en)	2007-10-31	Nucleobase characterisation
GB0711342D0 (en)	2007-07-25	Well treatment
GB0810364D0 (en)	2008-07-09	Improved effluent treatment
ZA201000225B (en)	2011-03-30	Treatment of depression
GB2455402B (en)	2010-05-05	Stimulation aid
GB0701145D0 (en)	2007-02-28	Freedom shower
GB0716784D0 (en)	2007-10-10	Well treatment
EP2176303A4 (en)	2010-09-01	MODIFICATION OF POLYOLEFINS
EG25492A (en)	2012-01-15	Defoliant
GB0723100D0 (en)	2008-01-02	Treatment of HFnEF
GB0723609D0 (en)	2008-01-09	Antiviral
GB0705204D0 (en)	2007-04-25	Uses of (S)-clenbuterol
AU3967P (en)	2010-02-03	CARDINAL Cordyline australis
GB0707534D0 (en)	2007-05-30	Enhanced fixation aids
AU318763S (en)	2008-04-08	Ceramic tub
GB0724838D0 (en)	2008-01-30	Effulent treatment
GB0710732D0 (en)	2007-07-18	Treatment